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Abstract 
 
 
Heterozygous germline gain-of-function mutations of G-protein subunit α11 (Gα11), a signaling 
partner for the calcium-sensing receptor (CaSR), result in autosomal dominant hypocalcemia 
type 2 (ADH2). ADH2 may cause symptomatic hypocalcemia with low circulating parathyroid 
hormone (PTH) concentrations. Effective therapies for ADH2 are currently not available and a 
mouse model for ADH2 would help in assessment of potential therapies. We hypothesised that a 
previously reported dark skin mouse mutant (Dsk7), which has a germline hypermorphic Gα11 
mutation, Ile62Val, may be a model for ADH2 and allow evaluation of calcilytics, which are 
CaSR negative allosteric modulators, as a targeted therapy for this disorder. Mutant Dsk7/+ 
and Dsk7/Dsk7 mice were shown to have hypocalcemia and reduced plasma PTH 
concentrations, similar to ADH2 patients. In vitro studies showed the mutant Val62 Gα11 to up-
regulate CaSR-mediated intracellular calcium and MAPK signaling, consistent with a gain-of-
function. Treatment with NPS-2143, a calcilytic compound, normalised these signaling 
responses. In vivo, NPS-2143 induced a rapid and marked rise in plasma PTH and calcium 
concentrations in Dsk7/Dsk7 and Dsk7/+ mice, which became normocalcemic. Thus, these 
studies have established Dsk7 mice, which harbor a germline gain-of-function Gα11 mutation, as 
a model for ADH2; and demonstrated calcilytics as a potential targeted therapy. 
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Introduction 
 
 
Autosomal dominant hypocalcemia (ADH) is a disorder of systemic calcium homeostasis caused by 
increased sensitivity of the calcium-sensing receptor (CaSR) signaling pathway to extracellular 
calcium (Ca2+o) concentrations (1, 2). The CaSR is a widely expressed class C G-protein coupled 
receptor (GPCR) that plays a pivotal role in Ca2+o homeostasis by transducing elevations in the 
prevailing Ca2+o concentration into multiple signaling cascades that include Gq/11-protein mediated 
activation of phospholipase C (PLC), which in the parathyroid glands induce increases in intracellular 
calcium (Ca2+i) and mitogen-activated protein kinase (MAPK) signaling responses that lead to 
decreased parathyroid hormone (PTH) secretion (3). ADH is associated with hypocalcemia, 
hyperphosphatemia, hypomagnesemia, inappropriately low or normal PTH concentrations, and some 
patients may also be hypercalciuric (1, 4), or develop a Bartter-like syndrome characterised by 
hypokalemic alkalosis, renal salt wasting and hyperreninemic hyperaldosteronism (5, 6). 
Approximately 50% of patients develop symptomatic hypocalcemia, and >35% have ectopic 
calcifications within the kidneys and basal ganglia (1, 2, 7, 8). ADH is a genetically heterogeneous 
disorder comprised of two variants, which are known as ADH type 1 (ADH1) and ADH type 2 
(ADH2). ADH1 (OMIM #601198) is caused by germline mutations of the CaSR, which is encoded by 
the CASR gene on chromosome 3q21.1 (1, 9); whereas, ADH2 (OMIM #615361) is caused by 
germline mutations of the widely expressed G-protein subunit α11 (Gα11) protein, which is encoded by 
the GNA11 gene on chromosome 19p13.3 (2, 7, 8, 10).  Both CaSR and Gα11 mutations identified in 
ADH patients have been demonstrated to enhance CaSR-mediated Ca2+i and MAPK signaling in 
cellular studies, consistent with a gain-of-function (1, 2, 7, 9-11).  
Mouse models with gain-of-function Casr mutations have been generated by chemical 
mutagenesis and knock-in strategies, and shown to have a phenotype closely resembling ADH1 in 
humans, with hypocalcemia, hyperphosphatemia, reduced PTH concentrations, hypercalciuria and 
ectopic calcifications (12, 13). Such models have been utilized to evaluate calcilytic compounds, 
which are negative allosteric CaSR modulators that represent a potential targeted therapy for ADH 
	 4	
(14-17). Indeed, a long-acting amino-alcohol calcilytic compound known as NPS-2143 has been 
shown in vivo to rectify the hypocalcemia of Nuf mice, which harbor a germline gain-of-function Casr 
mutation, Leu723Gln (13, 18). Recent in vitro studies have also revealed NPS-2143 to normalise the 
gain-of-function caused by Gα11 mutations that lead to ADH2 (11). However, it remains unclear 
whether this calcilytic may rectify the hypocalcemia associated with ADH2, and mouse models that 
harbor Gna11 mutations in association with hypocalcemia have not been reported to be available for 
such in vivo studies. Such mouse models would also aid the further phenotypic characterization of 
ADH2, as limited information is available from the small numbers of patients studied to date (2, 7, 8, 
10, 19). 
To develop a mouse model for ADH2, we conducted studies to investigate the calcitropic 
phenotype of a previously reported mouse mutant known as Gna11Mhdadsk7 or “dark skin 7”, and 
henceforth referred to as Dsk7, which has increased dermal pigmentation in association with a 
germline hypermorphic Gna11 mutation, Ile62Val (formerly referred to as Ile63Val) (20). We 
hypothesised that Dsk7 mice would exhibit dysregulation of Ca2+o homeostasis in keeping with 
ADH2. Our study has revealed Dsk7 mice to have hypocalcemia and reduced PTH concentrations, 
which are caused by a gain-of-function Gna11 mutation that leads to upregulation of CaSR-mediated 
Ca2+i and MAPK signaling responses. Moreover, we demonstrate that NPS-2143 treatment rectifies 
this gain-of-function in vitro and ameliorates the hypocalcemia of Dsk7 mice. 
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Results 
 
Genotype and phenotype studies of Dsk7 mice. DNA sequence analysis of Gna11 in Dsk7 mice 
confirmed the reported A-to-G transition (c.184A>G, RefSeq Accession NM_002067.4) at codon 62 
of the Gα11 protein resulting in an Ile to Val missense substitution (Supplementary Figure 1A-B) (20). 
This mutation also led to the loss of a FokI restriction endonuclease site (Supplementary Figure 1B), 
as reported (20), which was used to confirm the presence of the mutation in Dsk7 mice 
(Supplementary Figure 1C-D), and for genotyping of subsequent generations. Analysis of offspring 
bred from crosses of Dsk7/+ x Dsk7/+ mice showed that the proportion bred as homozygous-affected 
Dsk7/Dsk7 mice were >30% less (x2 =10.20, df = 2, P < 0.01) than would be expected from a 
Mendelian pattern of inheritance (Supplementary Table 1). The Dsk7/Dsk7 mice also had 
significantly reduced body weight and increased skin pigmentation (data not shown), when compared 
to age-matched WT (+/+) mice (Table 1), as previously reported (20).  
Biochemical analysis of plasma samples collected under isoflurane terminal anesthesia 
revealed male and female Dsk7/+ and Dsk7/Dsk7 mice to be significantly hypocalcemic and 
hyperphosphatemic, and to have significantly reduced PTH concentrations when compared to +/+ 
mice (Figure 1, Table 1). The hypocalcemia was significantly more marked in Dsk7/Dsk7 mice 
compared to heterozygous-affected Dsk7/+ mice (Figure 1, Table 1). Reduced FGF-23 concentrations 
were noted in Dsk7/Dsk7 mice compared to +/+ mice (Table 1). No significant differences were 
observed in plasma urea and creatinine concentrations, alkaline phosphatase activity or 1,25-
dihydroxyvitamin D concentrations (Table 1). Twenty-four hour urinary calcium excretion and 
urinary calcium/creatinine ratios were significantly reduced in female Dsk/+ mice, although fractional 
excretion of calcium was not different between either male or female Dsk7 mice and respective +/+ 
mice (Table 2). The tubular maximum reabsorption of phosphate was significantly increased in 
Dsk7/+ and Dsk7/Dsk7 mice (Table 2), consistent with the low circulating PTH concentrations of 
these mice (Figure 1, Table 1) (21). Fractional excretion of sodium and potassium were not altered 
(Table 2). Whole body dual-energy X-ray absorptiometry (DXA) showed no differences in bone 
mineral density (BMD) between male and female Dsk7 mice and respective +/+ mice (Table 3). 
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Micro-CT analysis of trabecular bone also showed no alterations in the bone volume fraction, or in 
the thickness or number of trabeculae between male or female Dsk7 mice and respective +/+ mice 
(Table 3). Ophthalmological examination did not reveal any lens opacifications in Dsk7/Dsk7 mice 
(data not shown), and these findings contrast with Nuf mice, which harbor a gain-of-function Casr 
mutation in association with hypocalcemia and cataracts (18). 
 
Effects of Ile62Val Gα11 mutation on Gα11 structure and CaSR-mediated signaling. The Ile62 residue 
is located within the α1 helix of the GTPase domain of Gα11, and close to the Arg60 residue, which 
has been reported to be mutated in ADH2 patients (Figure 2A) (7, 8).	The WT Ile62 residue, which is 
encoded in exon 2 of the Gna11 gene (Figure 2A), is absolutely conserved in Gα11 orthologs and 
highly conserved in Gα-subunit paralogs (Figure 2B). To determine the importance of the WT Ile62 
residue for Gα11 function, homology modeling was undertaken using the crystal structure of the 
related Gαq and Gαi proteins (22, 23). This revealed the WT Ile62 residue to be located at the interface 
between the Gα-subunit helical and GTPase domains (Figure 2C), and to comprise part of a conserved 
hydrophobic cluster of amino acid residues within the GTPase domain of the Gα-subunit, which play 
a key role in stabilizing G-proteins in an inactive GDP-bound conformation (Figure 2D) (23). These 
findings predicted that mutation of the conserved WT Ile62 Gα11 residue to a mutant Val62 residue 
would destabilize the inactive GDP-bound Gα-subunit, thereby leading to guanine-nucleotide 
exchange and Gα11 activation (23).  
To determine the effects of these predicted changes in Gα11 structure on CaSR-mediated 
signaling, HEK293 cells stably expressing the CaSR (HEK-CaSR) were transiently transfected with 
pBI-CMV2-GNA11 constructs expressing either the WT (Ile62) or mutant (Val62) Gα11 proteins. This 
bidirectional pBI-CMV2 vector allows for co-expression of Gα11 and GFP at equivalent levels (2); 
and expression of the CaSR, Gα11 and GFP was confirmed by fluorescence microscopy and/or 
Western blot analyses (Figure 3A-B). The expression of Gα11 was shown to be similar in cells 
transiently transfected with WT or mutant proteins, and greater than that observed in untransfected 
cells (Supplementary Figure 2). The expression of mutant Gα11 in transfected cells together with that 
of the endogenous expression of WT Gα11 corresponds to the heterozygous situation in vivo (Figure 
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3B and Supplementary Figure 2). The responses of Ca2+i to alterations in [Ca2+]o of cells expressing 
the different GNA11 vectors were assessed by flow cytometry. The Ca2+i responses in WT and mutant 
Gα11-expressing cells were shown to increase in a dose-dependent manner following stimulation with 
increasing concentrations of Ca2+o. However, responses in mutant Val62 expressing cells were 
significantly elevated compared to WT expressing cells (Figure 3C). Thus, the Val62 mutant-
expressing cells showed a leftward shift in the concentration-response curve (Figure 3C), with 
significantly reduced mean half-maximal response (EC50) value (P < 0.001, n=7) of 2.57 mM (95% 
confidence interval (CI) 2.47-2.67 mM) for Val62 expressing cells, compared to 3.02 mM (95% CI 
2.93-3.10 mM) for WT expressing cells (Figure 3D), consistent with a gain-of-function of the Gα11 
mutant, as observed with Gα11 mutations that lead to ADH2 (2, 7, 10, 11). The Val62 Gα11 mutant did 
not alter the maximal Ca2+i signaling responses (Figure 3E), but was associated with a significant 
reduction of the Hill coefficient (P < 0.01) (Figure 3F).  
 
In vitro effects of NPS-2143 treatment on Ca2+i and MAPK responses of the Val62 Gα11 mutant. To 
investigate whether allosteric inhibition of the CaSR can rectify the gain-of-function associated with 
the Ile62Val Gα11 mutation, NPS-2143 was added at 20 and 40 nM concentrations, as similar doses of 
this calcilytic have been reported to rectify the altered signaling responses associated with ADH2-
causing Gα11 mutations (11). An assessment of Ca2+i responses showed 20 nM NPS-2143 to increase 
the EC50 of Val62-expressing mutant cells to 2.97 mM (95% CI 2.88-3.08 mM), so that this was not 
significantly different from the EC50 of untreated WT cells (Figure 3C-D). However, addition of NPS-
2143 at the higher 40 nM dose increased the EC50 of mutant cells to a value of 3.48 mM (95% CI 
3.42-3.55 mM), which was significantly greater than that of untreated WT cells (P < 0.01)  (Figure 
3C-D). NPS-2143 had no effect on the maximal responses or Hill coefficients of mutant-expressing 
cells (Figure 3E-F).  
Some gain-of-function Gα11 mutations have been reported to promote tumorigenesis by 
constitutively upregulating MAPK signaling (24), and we therefore assessed the oncogenic potential 
of the Ile62Val Gα11 mutation in HEK-CaSR cells by measurements of phosphorylated ERK (pERK), 
which is a key component of the MAPK cascade (7, 25). WT and mutant pBI-CMV2-GNA11 vectors 
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were transiently transfected into HEK-CaSR cells and the fold-change increase in pERK proteins 
were measured following exposure to varying [Ca2+]o. Western blot analysis confirmed expression of 
WT and mutant Gα11 proteins in cells used for the pERK experiments (Figure 4A). In the absence of 
Ca2+o stimulation, the basal pERK responses of the Val62 mutant were not significantly different from 
cells expressing WT Gα11 (Figure 4B), whereas exposure to Ca2+o led to significantly increased pERK 
fold-change responses of cells expressing the Val62 Gα11 mutant (Val62 = 9.4±1.4) when compared to 
cells expressing WT Gα11 (Ile62 = 4.1±0.5, P < 0.01) (Figure 4B). NPS-2143 was next added to cells 
expressing the Val62 Gα11 mutant protein (Figure 4C), and which had been stimulated with 10 mM 
Ca2+o. Exposure to 20 nM of this calcilytic compound normalized the elevated pERK responses 
(Figure 4D). The effect of the Val62 Gα11 mutant on MAPK signaling was also investigated by 
measuring gene transcription induced by a serum-response element (SRE) containing luciferase 
reporter construct, which is a downstream mediator of ERK signaling (7, 25). Western blot analysis 
confirmed expression of WT and mutant Gα11 proteins in cells used for the SRE reporter experiments 
(Figure 4E). In the absence of Ca2+o stimulation, the basal SRE reporter activity of the Val62 mutant 
was not significantly different from cells expressing WT Gα11 (Figure 4F), whereas Ca2+o stimulation 
led to significantly increased SRE reporter fold-change responses of cells expressing the Val62 Gα11 
mutant (Val62 = 20.7±1.5 compared to 11.0±0.4 for the Ile62 WT Gα11, P < 0.05) (Figure 4F). NPS-
2143 was then added at a dose of 20 nM to cells expressing the Val62 Gα11 mutant protein (Figure 
4G), in the presence of 10 mM Ca2+o, and this normalized the increased SRE reporter responses 
(Figure 4H). 
  
In vivo effects of NPS-2143 on the hypocalcemia of Dsk7 mice. We next assessed whether the 
hypocalcemia of Dsk7 mice may be improved by treatment with NPS-2143. Previous studies have 
demonstrated that i.p. administration of a 30 mg/kg NPS-2143 dose significantly increases plasma 
calcium and PTH concentrations in Nuf mice with a gain-of-function Casr mutation, but is associated 
with adverse effects on renal function (13). In contrast, a study using oral gavage administration of 
NPS-2143 in WT rats has reported that a dose of 100 µmol/kg can increase PTH responses without 
adverse renal effects (26). We therefore evaluated the effects of i.p. and oral gavage administration of 
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NPS-2143 in +/+ mice, and showed that a single oral gavage 100 µmol/kg dose of NPS-2143 
significantly increased plasma calcium without altering renal function, whereas i.p. injection of this 
calcilytic led to a significant rise in plasma urea and creatinine (Supplementary Figure 2). We 
therefore administered a 100 µmol/kg bolus of NPS-2143 by oral gavage to +/+, Dsk7/+ and 
Dsk7/Dsk7 mice and measured PTH, calcium, phosphate, urea and creatinine concentrations at 0, 1, 2, 
6 and 24h post-dose using plasma samples obtained from the lateral tail vein following application of 
topical local anesthesia. Administration of NPS-2143 led to a 4-5-fold elevation in plasma PTH 
concentrations in +/+, Dsk7/+ and Dsk7/Dsk7 mice, with a maximal rise in PTH occurring at 1-2h 
post-dose (Figure 5A-C). The rise in PTH was associated with a significant increase in plasma 
calcium concentrations in +/+, Dsk7/+, and Dsk7/Dsk7 mice, which were maximally elevated (0.25-
0.5 mmol/L above baseline values) at 2h post-dose (Figure 5D-F). Indeed, administration of 100 
µmol/kg NPS-2143 normalised the plasma calcium concentrations of Dsk7/Dsk7 mice, whereas 
Dsk7/+ mice became transiently hypercalcemic (Figure 5D-F). NPS-2143 treatment also led to a 
transient rise in plasma phosphate concentrations in +/+ and Dsk7/Dsk7 mice (Figure 5G-I), which 
was not associated with any increases in plasma urea or creatinine (Supplementary Figure 3). Thus, 
these studies demonstrate that a single dose of NPS-2143 can rectify the hypocalcemia of Dsk7/+ and 
Dsk7/Dsk7 mice.  
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Discussion 
 
 
Our studies have demonstrated that Dsk7 mice, which harbor a germline Ile62Val Gna11 mutation 
(24), are hypocalcemic, hyperphosphatemic and have reduced circulating PTH concentrations. Thus, 
Dsk7 mice represent a mouse model for the human disorder of ADH2, which is caused by gain-of-
function GNA11 mutations (2, 7, 8, 10). In support of this, the Ile62Val Gα11 mutant protein enhanced 
the signaling responses of CaSR-expressing cells in vitro, and this data indicates that the Gna11 
mutation is leading to the observed phenotype in Dsk7 mice. The Ile62Val Gna11 mutation showed a 
gene dosage effect with the heterozygous-affected Dsk7/+ mice having an ~0.3 mmol/L decrease in 
plasma calcium and ~65% reduction in PTH concentrations compared to +/+ mice, whereas 
homozygous-affected Dsk7/Dsk7 mice have significantly more pronounced hypocalcemia (plasma 
calcium ~0.5 mmol/L lower than +/+ mice) and a greater (~85%) reduction in PTH concentrations 
(Figure 1, Table 1). The more severe hypocalcemia of homozygous-affected mice may potentially 
have affected their viability, thereby providing an explanation for the observed reduced numbers of 
mice with this genotype. The degree of hypocalcemia of affected Dsk7 mice is similar to that of 
ADH2 patients, who have been reported to have serum calcium values ranging between 0.1-0.6 
mmol/L below that of unaffected family members (7, 8, 27). Moreover, Dsk7 mice generally had 
detectable circulating PTH concentrations and also a normal fractional excretion of calcium, which is 
in keeping with the majority of ADH2 patients (2, 7, 8). The markedly reduced circulating PTH of 
Dsk7/Dsk7 mice was not significantly associated with decreases in plasma 1,25-dihydroxyvitamin D 
concentrations (Table 1), and such effects of PTH may have been counteracted by the low plasma 
FGF-23 concentrations, which would be expected to increase 1,25-dihydroxyvitamin D (28). Serum 
FGF-23 concentrations have not been reported for ADH2 patients, and our finding of low FGF-23 
values in Dsk7/Dsk7 mice was most likely a consequence of the hypocalcemia, which has been 
previously shown to reduce circulating FGF-23 concentrations in parathyroidectomized rats and in 
rats with hypocalcemia due to dietary calcium restriction (29). However, the mechanism by which 
hypocalcemia lowers FGF-23 remains to be established (29). The bone phenotype of ADH2 has been 
evaluated in a single kindred by plain radiography and no abnormalities were identified (19). Our 
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skeletal assessment of Dsk7 mice also did not reveal any major alterations in BMD, trabecular volume 
or structure, which indicates that gain-of function Gα11 mutations may not lead to alterations in bone 
metabolism.  
In addition to Dsk7 mice having similar calcitropic features to ADH2 patients, Dsk7 mice 
may also share some non-calcitropic phenotypes with affected patients. Indeed, short stature has been 
reported in two ADH2 kindreds (7, 19), and in keeping with this, Dsk7/Dsk7 mice have been 
previously noted to have significantly reduced body length and weight compared to +/+ mice (20). 
However, a key species-specific difference is that Dsk7/+ and Dsk7/Dsk7 mice have increased skin 
pigmentation, due to an expansion of the melanocyte population within the dermis (30), and such 
alterations in skin colour have not been reported for ADH2 patients to date. The studies of Dsk7 mice 
and ADH2 patients have also revealed differences to the phenotype of ADH1, which is caused by 
gain-of-function CASR mutations (1, 9). In particular, ADH1 patients and knock-in mice harboring 
ADH1-causing Casr mutations, have been demonstrated to have a relative or absolute hypercalciuria, 
and high bone mass (1, 12), in addition to hypocalcemia and low circulating PTH concentrations. 
These alterations in parathyroid, renal and bone metabolism observed in ADH1 are in keeping with 
the known expression and function of the CaSR in these tissues (31-33). In contrast, our finding that 
Dsk7 mice have hypocalcemia and low PTH values in the absence of renal or bone abnormalities, 
suggests that germline Gα11 mutations may influence CaSR signaling responses in the parathyroid 
gland without perturbing the function of this GPCR in other calcitropic tissues (Figure 1, Table 1). In 
support of this, studies of mice with a parathyroid-specific ablation of the Gq/11 proteins (34), have 
demonstrated a critical role for these proteins in PTH secretion, whereas it remains to be established if 
these G-proteins act as a signaling partner for the CaSR in the kidneys and bone. Moreover, the lack 
of a renal or bone phenotype in Dsk7 mice may also have been caused by alterations in the relative 
expression of Gα11 and Gαq. Thus, if Gαq expression predominates in kidney and bone, then a gain-of-
function of Gα11 may have been insufficient to alter CaSR signaling responses in these tissues. An 
additional difference in the phenotypes associated with gain-of-function mutations of the CaSR and 
Gα11 proteins, respectively, is that Nuf mice, which have hypocalcemia in association with a germline 
Casr mutation, Leu723Gln, developed cataracts by 4-6 weeks of age (18), whereas Dsk7 mice do not 
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have lens abnormalities. The CaSR has been reported to be expressed and functionally linked to Ca2+-
activated K+ channels in lens epithelial cells (35), however its role in cataract formation has not been 
determined. The absence of lens opacifications in Dsk7 mice indicates that alterations in CaSR-
mediated Gα11 signaling may not be involved in the development of this eye disorder. 
Our findings help to elucidate some of the mechanisms whereby the germline Ile62Val Gα11 
mutation, which involves the substitution of amino acid residues with similar hydrophobic properties, 
cause a gain-of-function and enhance the sensitivity of CaSR expressing cells to Ca2+o. The WT Gα11 
Ile62 residue appears to be absolutely conserved amongst multicellular organisms, and is located 
within the Gα-subunit α1 helix at the interdomain interface, which contains a hydrophobic cluster of 
residues involved in guanine nucleotide binding (Figure 2) (23). Upon binding of G-protein to GPCR, 
the α1 helix has been shown to undergo conformational changes that destabilize the interdomain 
interface, thereby leading to the exchange of GDP for GTP (23), which triggers G-protein activation. 
It is likely that the Ile62Val mutation leads to a gain-of-function by decreasing the stability of the α1 
helix, and this possibility is supported by reported mutagenesis studies involving the related Gαi 
protein, which have shown substitution of the homologous Gαi Ile residue with alanine to destabilize 
the GDP-bound form of the Gα-subunit (23). The Gα11 interdomain interface and hydrophobic residue 
cluster represent a hotspot for gain-of-function mutations, with 5 out of 6 of the reported ADH2-
causing mutations situated within this region (2, 7, 8, 10), consistent with our proposal that these 
mutations likely alter the conformation of the guanine nucleotide-binding pocket, thereby promoting 
GDP-GTP exchange and G-protein activation. 
 Although the Val62 Gα11 mutant protein enhanced the Ca2+i responses of CaSR-expressing 
cells, consistent with a gain-of-function, it also significantly reduced the Hill coefficient, which was 
not rectifiable with calcilytic treatment (Figure 3). The Hill coefficient is commonly used to represent 
cooperative receptor-ligand interactions (36), but may also indicate the degree of interaction between 
a GPCR and its downstream partner signaling protein (25). Our finding of a reduced Hill coefficient 
suggests that the Ile62Val mutation may have altered coupling of the mutant Gα11 protein with the 
CaSR. In support of this, ADH1-causing mutations located within the CaSR transmembrane domain, 
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which is predicted to be the site of G-protein binding, have also been reported to lower the Hill 
coefficient, whilst leading to a gain-of-function (37). 
The most severe clinical manifestation of GNA11 mutations is uveal melanoma, which is a 
malignant tumor arising from the melanocytes of the choroid plexus, ciliary body and iris, and caused 
by somatic mutations of the Arg183 and Qln209 Gα11 residues that lead to constitutive upregulation of 
MAPK signaling (24). As the Ile62Val Gna11 mutation is associated with increased proliferation of 
melanocyte precursors in Dsk7 mice (20), we assessed the oncogenic potential of this mutation in 
vitro, and demonstrated that it increased MAPK responses only in the presence of Ca2+o stimulation 
(Figure 4). Thus, the Ile62Val Gα11 mutant does not harbor constitutive activity, and these findings are 
consistent with previously reported ADH2 mutations, which also lead to a non-constitutive gain-of-
function (7, 11), and are supported by studies of double mouse mutants, which have shown that the 
Ile62Val Gna11 mutation does not cause increased skin pigmentation in the absence of an upstream 
functional receptor (20). 
 ADH2 is frequently associated with hypocalcemic symptoms such as paraesthesia, muscle 
cramps, carpo-pedal spasm and seizures (2, 7, 8, 10). However, treatment of symptomatic patients 
with calcium and active vitamin D preparations has resulted in adverse effects such as hypercalciuria, 
nephrocalcinosis and nephrolithiasis (7, 10). Although calcilytic compounds represented targeted 
therapies for patients with CaSR mutations causing symptomatic forms of ADH1 (12, 13), it was 
unclear if these CaSR allosteric modulators may rectify abnormalities of the downstream Gα11 protein, 
and thus have potential benefit for ADH2 patients. Recent in vitro studies have revealed that low 
doses (10-30 nM concentrations) of the NPS-2143 calcilytic compound can successfully correct the 
gain-of-function associated with ADH2-causing Gα11 mutations (11). Consistent with these findings, a 
similar dose of NPS-2143 also normalised the Ca2+i and MAPK responses of the Ile62Val Gα11 mutant 
(Figure 3). Moreover, we have shown that administration of a single NPS-2143 dose induced a rapid 
and marked rise in PTH concentrations in Dsk7/+ and Dsk7/Dsk7 mice, and rectified or improved 
their hypocalcemic phenotypes, respectively (Figure 5); these data suggest that Dsk7/Dsk7 mice will 
likely require a higher dose of NPS-2143 to correct their hypocalcaemia. These results suggest that 
calcilytics such as NPS-2143 will likely be of benefit for ADH2 patients, who also harbor 
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heterozygous GNA11 mutations (2, 7, 8, 10). Oral administration of NPS-2143 was well tolerated, and 
the acute rise in plasma calcium post-dose did not affect the health or condition of the mice, or 
influence biochemical parameters such as electrolytes or renal function. However, an increase in 
plasma phosphate was noted in WT mice following treatment with NPS-2143, and this finding has 
also been reported in Nuf mice, which became hyperphosphatemic and had increases in urea and 
creatinine following a single i.p. injection of NPS-2143 (13). However, the rise in phosphate observed 
in the present study was not associated with alterations in renal function, and the cause of the 
hyperphosphatemia remains to be elucidated. Longer-term studies involving repetitive dosing are 
required to confirm the efficacy and safety of calcilytics for improving circulating calcium 
concentrations in the setting of ADH2. Of note, blood samples obtained from mice under isoflurane 
terminal anesthesia (Table 1) showed significant elevations in plasma concentrations of phosphate and 
PTH compared to samples obtained using topical local anesthesia (Supplementary Figure 5). General 
anesthetics, which include inhalation agents such as isoflurane, have been reported in laboratory 
animal studies to significantly alter plasma concentrations of phosphate and PTH (38, 39). Our 
findings further highlight the effects of anesthetic agents on these commonly measured biochemical 
parameters. 
 In conclusion, we have established that Dsk7 mice, which harbor a germline gain-of-function 
Gα11 mutation, represent an in vivo model for the human disorder of ADH2. We have also utilized this 
model to demonstrate that calcilytic compounds have the potential to treat the hypocalcemia 
associated with this disorder. 
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Methods 
 
Animals 
Dsk7 mice were re-derived on a C3H strain background (C3H.C3HeB/FeJ-Gna11Mhdadsk7/IegH) by in 
vitro fertilisation using sperm obtained from the European Mutant Mouse Archive (EMMA). All 
study mice were aged between 12-16 weeks and housed in a controlled environment at the Medical 
Research Council (MRC) Harwell Institute in accordance with UK Home Office and MRC welfare 
guidance. Mice had free access to water and were fed ad libitum on a commercial diet (RM3, Special 
Diet Services, UK) that contained 1.15% calcium, 0.58% phosphate and 4089 IU/kg of vitamin D.  
 
Compounds 
NPS-2143 hydrochloride (also known as 2-Chloro-6-[(2R)-3-[[1,1-dimethyl-2-(2-
naphthalenyl)ethyl]amino]-2-hydroxypropoxy]-benzonitrile hydrochloride) was obtained from Sigma-
Aldrich (catalog no. SML0362) and dissolved in a 20% aqueous solution of 2-hydroxypropyl-β-
cyclodextrin (Sigma-Aldrich, catalog no. H107) prior to use in in vitro and in vivo studies. 
 
DNA sequence analysis 
Genomic DNA was extracted from auricular biopsies, as described (40), and gene-specific primers 
were used to perform PCR amplification and DNA sequence analysis of Gna11 exon 2, as reported 
(2). The germline Gna11 mutation was confirmed by FokI restriction endonuclease analysis (New 
England Biolabs), as previously described (20). 
 
Protein Sequence Alignment and Three-dimensional modeling  
Protein sequences of Gα11 were aligned using ClustalOmega 
(http://www.ebi.ac.uk/Tools/msa/clustalo/) (41). PyMOL Molecular Graphics System (Version 
1.2r3pre, Schrödinger, LL Pymol) (16) was used to model the effects of the Gα11 Ile62Val mutation. 
Gα11 three-dimensional modeling was undertaken using the reported three-dimensional structure of 
Gαq in complex with the small molecule inhibitor YM-254890 (Protein Data Bank accession no. 
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3AH8) (22) and also using the reported structure of the Gαi protein (Protein Data Bank accession no. 
1GDD) (23). 
 
Cell culture and protein expression  
Functional studies were undertaken using a human GNA11 construct (2), as the human and mouse 
Gα11 proteins share an overall amino acid identity of 98%, and are 100% identical in the region 
surrounding the mutated site. The Val62 mutation was introduced by site-directed mutagenesis 
(QuikChange Lightning, Agilent Technologies) into a pBI-CMV2-GNA11 expression construct, as 
described (2). WT and mutant pBI-CMV2-GNA11 constructs were transiently transfected into 
HEK293 cells that stably express the full-length human CASR cDNA (HEK-CaSR), as described (2, 
42, 43). HEK293 cells were used because suitable parathyroid and renal tubular cells are not 
available, and HEK293 cells have been established as a model for the functional expression of Gα11 
proteins (2, 43, 44). HEK-CaSR cells were cultured in high-glucose DMEM (Invitrogen) 
supplemented with 10% fetal bovine serum and 1% geneticin at 37°C, 5% CO2 (2). Successful 
transfection was confirmed by visualising GFP fluorescence using an Eclipse E400 fluorescence 
microscope with an epifluorescence filter, and images were captured using a DXM1200C digital 
camera and NIS Elements software (Nikon) (2, 44). The expression of Gα11 and CaSR proteins was 
confirmed by Western blot analyses using Gα11 (D-6, sc-390382, Santa Cruz Biotechnologies), anti-
GFP (B-2, sc-9996, Santa Cruz Biotechnologies), anti-calnexin (AB2301, Millipore), anti-GAPDH 
(AM4300, Ambion) or anti-CaSR (5C10, ADD, ab19347, Abcam) antibodies. The Western blots 
were visualised using an Immuno-Star Western C kit (BioRad) on a BioRad Chemidoc XRS+ system 
(2, 42). Densitometric analysis was performed using Image J analysis software (Version 1.46; 
rsb.info.nih.gov/ij/) and statistical analysis performed using two-way ANOVA, as previously 
described (45). 
 
Measurement of Ca2+i responses 
The effect of the mutant Gα11 protein on the Ca2+i responses of CaSR-expressing cells was assessed 
by a flow cytometry-based assay, as reported (2, 43, 44). Briefly, 48h after transfection, the cells were 
	 17	
harvested, washed in calcium- and magnesium-free HBSS (Invitrogen) and loaded with 1g/ml indo-
1-acetoxymethylester (Indo-1-AM) (Molecular Probes) for 1h at 37°C (2, 43, 44). After the removal 
of free dye, the cells were resuspended in calcium- and magnesium-free HBSS and maintained at 
37°C. Transfected HEK-CaSR cells were incubated with either a 20% aqueous solution of 2-
hydoxypropyl--cyclodextrin (vehicle), or negative allosteric modulator NPS-2143 at concentrations 
of 20 and 40nM for 1h, as previously described (11). 
 Transfected cells in suspension were then stimulated by sequentially adding calcium to 
increase the [Ca2+]o in a stepwise manner from 0 to 15 mM, and then analysed on a MoFlo modular 
flow cytometer (Beckman Coulter) by simultaneous measurement of GFP expression (at 525nm), 
Ca2+i-bound Indo-1AM (at 410nm), and free Indo-1AM (at 485nm), using a JDSU Xcyte UV laser 
(Coherent Radiation), on each cell at each [Ca2+]o, as described (2, 42, 43). Cytomation Summit 
software was used to determine the peak mean fluorescence ratio of the transient response after each 
individual stimulus expressed as a normalized response (2, 42, 43). Concentration-response curves 
were generated using a 4-parameter non-linear regression curve-fit model (GraphPad Prism) to 
calculate the half-maximal (EC50) and Hill coefficient values (1, 7, 19). The maximal signaling 
response was measured as a fold-change of the peak transient Ca2+i response to the basal Ca2+i 
response. The maximal signaling response of mutant-expressing cells was expressed as a percentage 
of the WT maximal signaling response. 
 
Measurement of ERK1/2 phosphorylation 
HEK-CaSR cells were seeded in 48-well plates and transfected with 200ng WT or mutant Gα11 
proteins 24h prior to conducting the assays. Transfected cells were incubated in serum-free media 12h 
prior to treatment of cells with 0-10mM CaCl2. Cells were lysed in Surefire lysis buffer, and 
AlphaScreen Surefire ERK assays measuring phosphorylated and total proteins were performed as 
previously described (11). For studies with negative allosteric modulators, cells were incubated with 
either a 20% aqueous solution of 2-hydoxypropyl--cyclodextrin (vehicle), or NPS-2143 for 4h prior 
to being stimulated with 10 mM CaCl2. The fluorescence signal in both assays was measured using 
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the PheraStar FS microplate reader (BMG Labtech) (11, 45).  
 
Measurement of serum response element (SRE) luciferase reporter activity 
HEK-CaSR cells were seeded in 48-well plates and transiently transfected with 100ng/ml Gα11 WT or 
mutant proteins, 100ng pGL4-SRE luciferase reporter construct and 10ng/ml pRL control vector for 
48h. Cells were incubated in serum-free media for 12h, followed by treatment of cells for 4h with 0-
10mM CaCl2. Cells were lysed and assays performed using Dual-Glo luciferase (Promega) on a 
Veritas Luminometer (Promega), as previously described (44, 45). 
 
Plasma biochemistry and hormone analysis 
Blood samples were collected from the lateral tail vein of study mice following application of topical 
local anesthesia, as reported (40) or collected from the retro-orbital vein under isoflurane terminal 
anesthesia. Lateral tail vein sampling provides small volumes of blood that are adequate for analysis 
of plasma calcium, albumin, phosphate, PTH, urea and creatinine. However, retro-orbital vein 
sampling under terminal general anaesthesia, is required to obtain larger blood volumes that permit 
analysis of a wider range of biochemical parameters. Plasma was separated by centrifugation at 5000g 
for 10 min at 8°C, and analyzed for sodium, potassium, total calcium, magnesium, phosphate, urea, 
creatinine, albumin, and alkaline phosphatase on an Beckman Coulter AU680 analyzer, as described 
previously (13). Plasma calcium was adjusted for variations in albumin concentrations using the 
formula: (plasma calcium (mmol/L) – [(plasma albumin (g/L) – 30) x 0.02], as reported (40). 
Hormones were measured as follows: PTH using a two-site ELISA kit (Immunotopics); Intact FGF-
23 using a two-site ELISA kit (Kainos Laboratoties, Tokyo, Japan); and 1,25-dihydroxyvitamin D 
measured by a two-step process involving purification by immunoextraction and quantification by 
enzyme immunoassay (Immunodiagnostic Systems, Boldon, UK), as described (46). 
 
Metabolic cages and urine biochemistry analysis  
Mice were individually housed in metabolic cages (Techniplast), and fed ad libitum on water and 
powdered chow. Mice were allowed to acclimatise to their environment over a 72h period, as 
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described (47), prior to collection of 24h urine samples. Urine was analyzed for sodium, potassium, 
creatinine, phosphate and calcium on a Beckman Coulter AU680 analyzer, as reported (18). The 
fractional excretion of sodium, potassium, and calcium were calculated using the formula 
Ux/Px*PCr/UCr, where Ux is the urinary concentration of the filtered substance (substance x) in 
mmol/L, Px is the plasma concentration of substance x in mmol/L, UCr is the urinary concentration of 
creatinine in mmol/L, and PCr is the plasma concentration of creatinine in mmol/L (13). The ratio of 
tubular maximum reabsorption of phosphate to GFR (TmP/GFR) was calculated using the following 
formula: PPi*(1-(UPi/PPi*PCr/UCr )), where PPi is the plasma concentration of phosphate and UPi is the 
urine concentration of phosphate. 
 
Skeletal imaging 
 
Bone mineral density was assessed by whole body DXA scanning, which was performed on mice 
anesthetized by inhaled isoflurane, and using a Lunar Piximus densitometer (GE Medical Systems), as 
reported (46). DXA images were analysed using Piximus software, as reported (46). Trabecular bone 
volume and structure were assessed by micro-CT analysis of the proximal tibia using a Skyscan 1174 
scanner (SkyScan, Belgium), with X-ray settings 50kV, 800µA, 12.6 µm isometric voxel resolution, 
and 0.7 degree rotation step. The tibial trabecular region, located 1.5 mm distally from the growth 
plate, was selected for analysis, and a volume of interest was delineated by drawing within the cortex 
of the trabecular region. A threshold of 80-255 density units was selected to distinguish mineralized 
trabecular tissue from surrounding soft tissue of the marrow cavity. Cross-sectional images were 
obtained and 3-D reconstruction undertaken using Skyscan CT Analyzer software (version 1.9.3.0).  
 
 
In vivo administration of NPS-2143 
 
NPS-2143 was administered as a single 100 µmol/kg (~45 mg/kg) dose by oral gavage, or as a single 
30 mg/kg dose by i.p. injection, as described (13), and plasma samples collected by tail vein bleed at 
either 0, 1, 2, 6 or 24h post-dose.  
 
 
	 20	
Statistical analysis 
All in vitro studies involved between 2-12 separate transfection experiments and between 4-8 
technical assays. For the in vitro measurement of Ca2+i EC50 responses, statistical comparisons were 
undertaken using the F-test (1, 7, 19), whereas, Ca2+i maximal signaling responses and Hill 
coefficients were analysed using the Mann-Whitney U test.  Measurements of ERK phosphorylation 
and SRE gene luciferase reporter activity were analyzed using the Mann-Whitney U test or by 2-way 
ANOVA with Tukey’s multiple-comparisons test. For the in vivo studies, a Kruskal-Wallis test was 
undertaken for multiple comparisons, and any significant differences identified were further assessed 
using the Dunn’s test for non-parametric pairwise multiple comparisons. All analyses were 
undertaken using GraphPad Prism (GraphPad), and a value of p<0.05 was considered significant for 
all analyses.  
 
Study approval 
Animal studies were approved by the MRC Harwell Institute Ethical Review Committee and were 
licensed under the Animal (Scientific Procedures) Act 1986, issued by the UK Government Home 
Office Department (PPL30/3271). 
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Figure legends 
 
Figure 1. Calcitropic phenotype of Dsk7 mice. (A-B) plasma adjusted-calcium, (C-D) plasma 
phosphate, and (E-F) plasma PTH concentrations of male and female WT (+/+, circles), Dsk7/+ 
(squares) and Dsk7/Dsk7 (triangles) mice, respectively. Mean ± SEM values for the respective groups 
are indicated by the solid bars. *P < 0.05, **P < 0·01. ***P < 0.001. A Kruskal-Wallis test followed 
by Dunn’s test for non-parametric pairwise multiple comparisons were used for analysis of A-F. 
 
Figure 2. Structural characterization of the Ile62Val Gα11 mutation. (A) Genomic organization of 
Gna11 showing location of the Ile62Val mutation. The Gα11 GTPase domain (encoded by exon 1, 5’ 
portion of exon 2, 3’ portion of exon 4 and exons 5 to 7) is connected to the helical domain (encoded 
by the 3’ portion of exon 2, exon 3, and 5’ portion of exon 4) by the linker 1 (L1) and 2 (L2) peptides. 
The Ile62Val mutation (red) lies within the α1-helix (green). The location of reported ADH2 
mutations are indicated (black). (B) Multiple protein sequence alignment of residues comprising the 
α1 helix and L1 peptide of Gα11-subunit orthologs (top) and Gα-subunit paralogs (bottom). Conserved 
residues are shown in gray. The WT (Ile) and Dsk7 mutant (m) (Val) residues are shown in red. (C) 
Homology model of the Gα11 protein. The Gα helical (blue) and GTPase (green) domains are 
connected by the L1 and L2 peptides (gray). GDP (black) is bound at the interdomain interface. 
Previously reported residues mutated in ADH2 are shown in yellow. The mutated Ile62 residue is 
shown in red. (D) Close-up view of the Ile62 residue which lies within a hydrophobic cluster of 
residues (blue spheres) on α1, α5 and β1 of the GTPase domain, and near to the interdomain interface 
(dotted line) and GDP binding site. 
 
Figure 3. Intracellular calcium responses of the Val62 Gα11 mutant and effect of NPS-2143 
treatment. (A) Fluorescence microscopy of HEK293 cells stably expressing CaSR (HEK-CaSR) and 
transiently transfected with WT Ile62 or mutant (m) Val62 pBI-CMV2-GNA11 constructs. GFP 
expression in these cells indicates successful transfection and expression by these constructs. Bar 
indicates 10µm. (B) Western blot analysis of lysates from HEK-CaSR cells used for flow cytometry 
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experiments. Transient transfection with WT or mutant Val62 expression constructs resulted in 
overexpression of Gα11 and GFP. Calnexin, a housekeeping protein, and untransfected cells 
(Supplementary Figure 2) were used as controls. (C) Ca2+i response to changes in [Ca2+]o of HEK-
CaSR cells transfected with WT or Val62 Gα11 mutant. The Ca2+i responses to changes in [Ca2+]o are 
expressed as a percentage of the maximum normalized responses and shown as the mean ± SEM of 5-
8 assays from two independent transfections. The Val62 Gα11 mutant led to a leftward shift in the 
concentration-response curve (red line). The addition of 20 nM NPS-2143 rectified the leftward shift 
of the Val62 Gα11 mutant (red dashed line), whereas 40 nM NPS-2143 led to a rightward shift of the 
mutant concentration-response curve (pink dashed line) compared to WT (black line). (D-F) 
Histograms showing mean ± SEM EC50 values, % maximal signaling responses, and Hill coefficients, 
respectively, for cells expressing WT (open bar) or Val62 Gα11 mutant (black bar) proteins, and for 
mutant-expressing cells treated with NPS-2143 (patterned bars). **P < 0.01, ***P <0.001. F-test for 
C-D. Mann-Whitney U test for E-F.  
 
Figure 4. MAPK responses of the Val62 Gα11 mutant and effect of NPS-2143 treatment. (A) 
Western blot analysis of lysates from HEK-CaSR cells used for phospho-ERK (pERK) experiments. 
(B) pERK fold-change responses to changes in [Ca2+]o of cells transfected with WT (solid line) or 
Val62 Gα11 mutant (dashed line). (C) Western blot analysis of lysates from cells used to assess effect 
of NPS-2143 (2143) on pERK responses (D) Effect of NPS-2143 on pERK responses of Val62 Gα11 
mutant. (E) Western blot analysis of lysates from HEK-CaSR cells used for serum response element 
reporter experiments. (F) SRE reporter fold-change responses to changes in [Ca2+]o of cells 
transfected with WT (solid line) or Val62 Gα11 mutant (dashed line). (G) Western blot analysis of 
lysates from cells used to assess effect of NPS-2143 on SRE reporter responses. (H) Effect of NPS-
2143 on the SRE reporter responses of the Val62 Gα11 mutant. The Val62 Gα11 mutant led to 
significantly increased pERK and SRE fold-change responses following stimulation with Ca2+o. In the 
absence of Ca2+o, the pERK and SRE responses of the Val62 Gα11 mutant were not significantly 
different from WT, thereby indicating the Ile62Val Gα11 mutation to be non-constitutively activating. 
The addition of 20 nM NPS-2143 decreased the pERK and SRE responses of cells expressing the 
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Val62 Gα11 mutant (patterned bars) compared to untreated cells (solid bars), so that these were not 
significantly different from WT (open bars). The fold-change responses are shown as the mean ± 
SEM of 4-8 independent transfections. *P < 0.05, **P < 0.01. Mann-Whitney U test for B, D, F and 
H. 
 
Figure 5.  Effect of NPS-2143 on plasma PTH, calcium and phosphate of Dsk7 mice at 0, 1, 2, 6 
and 24h post-dose. (A-C) plasma PTH, (D-F) plasma adjusted-calcium, and (G-I) plasma phosphate 
concentrations of WT (+/+), Dsk7/+ and Dsk7/Dsk7 mice, respectively. Mean values for the 
respective groups are indicated by solid bars. N=4-7 mice per study time-point. Squares, males; 
circles, females. *P < 0.05, **P < 0·01. A Kruskal-Wallis test followed by Dunn’s test for non-
parametric pairwise multiple comparisons were used for analysis of A-I. 
Table 1. Age, weight and plasma biochemical profile of WT and Dsk7 mice 
 
 Male Female 
 +/+ 
 
Dsk7/+ Dsk7/Dsk7 +/+ Dsk7/+ Dsk7/Dsk7 
Age (weeks) 
 
13.6±0.2 (n=27) 
 
13.5±0.2 (n=29) 
 
13.5±0.3 (n=17) 
 
13.7±0.3 (n=24) 
 
13.7±0.2 (n=31) 
 
13.7±0.2 (n=20) 
 
Weight (g) 
 
32.2±0.4 (n=11) 
 
33.9±0.6 (n=12) 
 
28.9±0.9*** (n=10) 
 
30.8±0.4 (n=11) 
 
29.4±1.1 (n=12) 
 
24.6±0.9* (n=7) 
 
Plasma biochemistry 
Sodium (mmol/L) 151±0.4 (n=12) 
 
151±0.9 (n=13) 150±0.2 (n=9) 148±1.1 (n=11) 
 
146±1.3 (n=12) 150±1.2 (n=7) 
Potassium (mmol/L) 5.5±0.1 (n=13) 
 
5.2±0.1 (n=12) 5.0±0.1 (n=10) 4.5±0.2 (n=11) 4.9±0.3 (n=11) 4.5±0.2 (n=7) 
Urea (mmol/L) 
 
12.6±0.4 (n=12) 11.5±0.4 (n=13) 12.9±0.2 (n=9) 9.1±0.6 (n=11) 8.7±0.8 (n=12) 10.9±1.0 (n=7) 
Creatinine (µmol/L) 11.9±0.5 (n=13) 
 
12.1±0.8 (n=12) 12.8±0.5 (n=10) 11.6±0.6 (n=11) 11.8±0.5 (n=12) 12.9±1.3 (n=7) 
Calcium (mmol/L)A 
 
2.51±0.02 (n=25) 2.20±0.01*** (n=25) 1.98±0.05*** (n=15) 2.45+0.03 (n=22) 2.19±0.02*** (n=29) 1.90±0.03*** (n=17) 
Magnesium(mmol/L) 0.86±0.02 (n=11) 0.82±0.02 (n=14) 0.87±0.02 (n=6) 
 
0.87±0.02 (n=10) 0.83±0.01 (n=17) 0.78±0.02 (n=10) 
Phosphate (mmol/L) 2.23±0.1 (n=20) 
 
3.01±0.07** (n=22) 3.96±0.24*** (n=13) 2.43±0.07 (n=13) 2.89±0.1* (n=19) 3.19±0.19** (n=15) 
ALP (U/L) 93.2±2.3 (n=12) 
 
95.3±2.8 (n=13) 93.3±5.2 (n=10) 120±8.4 (n=11) 127±4.9 (n=12) 121±8.5 (n=7) 
PTH (ng/L) 404±44 (n=12) 133±13** (n=12) 
 
64±19*** (n=6) 283±41 (n=11) 158±21* (n=16) 50±9*** (n=12) 
1,25D (pmol/L) 109±15 (n=14) 86±11 (n=13) 59±11 (n=5) 85±9 (n=13) 58±6 (n=16) 60±12 (n=12) 
 
FGF-23 (ng/L) 270±45 (n=10) 174±23 (n=13) 120±29$ (n=6) 200±39 (n=11) 110±14 (n=18) 74±13* (n=8) 
 
 
APlasma calcium concentrations were adjusted for the plasma albumin concentration. ALP, alkaline phosphatase activity; PTH, parathyroid hormone; 1,25D, 1,25 
dihydroxyvitamin D; FGF-23, fibroblast growth factor-23. All values are expressed as mean ± SEM. $P = 0.05; *P < 0.05, **P < 0.01, ***P < 0.001 compared to respective 
WT (+/+) mice. A Kruskal-Wallis test followed by Dunn’s test for non-parametric pairwise multiple comparisons were used for all analyses. 
  
Table 2. Urine biochemical profile of WT and Dsk7 mice 
 
 Male Female 
 +/+ Dsk7/+ Dsk7/Dsk7 +/+ Dsk7/+ Dsk7/Dsk7 
 
24hr Ca 2.14±0.28 (n=13) 
 
1.99±0.23 (n=13) 2.0±0.23 (n=10) 2.71±0.24 (n=11) 1.70±0.20* (n=12) 1.78±0.32 (n=7) 
Ca/Cr 0.22±0.01 (n=12) 
 
0.22±0.02 (n=13) 0.23±0.03 (n=10) 0.29±0.03 (n=11) 
 
0.19±0.01* (n=12) 0.23±0.03 (n=7) 
FECa 0.001±0.0001 (n=12) 
 
0.001±0.0001 (n=12) 0.001±0.0002 (n=9) 0.001±0.0001 (n=11) 
 
0.001±0.0003 (n=12) 0.002±0.0002 (n=7) 
FENa 0.004±0.0002 (n=13) 
 
0.004±0.0001 (n=12) 
 
0.004±0.0002 (n=10) 
 
0.003±0.0002 (n=11) 
 
0.004±0.0002 (n=12) 
 
0.004±0.0004 (n=7) 
 
FEK 
 
0.14±0.006 (n=13) 
 
0.14±0.007 (n=12) 0.18±0.02 (n=10) 0.12±0.007 (n=11) 
 
0.14±0.007 (n=11) 0.14±0.009 (n=7) 
TmP/GFR 2.4±0.2 (n=13) 
 
3.0±0.1* (n=13) 4.3±0.2*** (n=10) 2.4±0.1 (n=11) 
 
3.1±0.1** (n=12) 3.7±0.2*** (n=7) 
 
Parameters were measured using urine samples obtained over a 24-hour period. Urinary calcium excretion values are shown as µmol/24 hours. Calcium/creatinine ratios 
(Ca/Cr) are shown as mmol/mmol. FE, fractional excretion; TmP/GFR, ratio of tubular maximum reabsorption of phosphate (TmP) to GFR. All values are expressed as mean 
± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 compared to respective WT (+/+) mice. A Kruskal-Wallis test followed by Dunn’s test for non-parametric pairwise multiple 
comparisons were used for all analyses. 
Table 3. Bone parameters of WT and Dsk7 mice 
 
 Male Female 
 +/+ 
 
Dsk7/+ Dsk7/Dsk7 +/+ Dsk7/+ Dsk7/Dsk7 
Whole body DXA 
BMD  
(g/cm2) 
 
0.064±0.001 
(n=6) 
0.063±0.002 
(n=6) 
0.061±0.001 
(n=4) 
0.062±0.002 
(n=10) 
0.065±0.002 
(n=10) 
0.058±0.003 
(n=5) 
Proximal tibia micro-CT 
BV 
(mm3) 
 
0.78±0.04 
(n=6) 
0.71±0.04 
(n=6) 
0.65±0.03 
(n=6) 
1.10±0.08 
(n=6) 
1.10±0.08 
(n=6) 
1.10±0.06 
(n=6) 
BV/TV  
(%) 
27±1.7 
(n=6) 
 
27±1.0 
(n=6) 
29±2.1 
(n=6) 
50±3.7 
(n=6) 
52±2.3 
(n=6) 
60±1.0 
(n=6) 
Tb. Th  
(mm) 
 
0.10±0.001 
(n=6) 
0.98±0.002 
(n=6) 
0.10±0.003 
(n=6) 
0.14±0.005 
(n=6) 
0.15±0.005 
(n=6) 
0.16±0.006 
(n=6) 
Tb. N 
(mm-1) 
 
2.7±0.1 
(n=6) 
2.7±0.1 
(n=6) 
2.8±0.1 
(n=6) 
3.5±0.1 
(n=6) 
3.5±0.1 
(n=6) 
3.6±0.1 
(n=6) 
SMI 
 
 
1.9±0.2 
(n=6) 
1.7±0.1 
(n=6) 
1.8±0.1 
(n=6) 
0.7±0.2 
(n=6) 
0.5±0.2 
(n=6) 
-0.1±0.2 
(n=6) 	
DXA, dual-energy X-ray absorptiometry; BMD, bone mineral density; BV, bone volume; BV/TV, cancellous bone 
volume fraction as a proportion of total possible organ (“tissue”) volume; Tb. Th, trabecular thickness; Tb. N, 
trabecular number; SMI, structural model index. All values are expressed as mean ± SEM. A Kruskal-Wallis test 
followed by Dunn’s test for non-parametric pairwise multiple comparisons were used for all analyses. 
 
  





Supplementary Table 1. Proportion of offspring bred from crosses of Dsk7/+ x Dsk7/+ mice 	
Genotype Expected number of offspring (n=584 
born) 
 
Observed number of offspring  
(n=482 weaned) 
+/+ 
 
146 (25%) 128 (27%) 
Dsk7/+ 
 
292 (50%) 272 (56%) 
Dsk7/Dsk7 
 
146 (25%) 82 (17%) 	
Chi-square analysis showed the observed proportion of offspring to be different from those expected (x2 =10.20, 
df = 2, P < 0.01), with significantly fewer Dsk7/Dsk7 mice being bred. 
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Supplementary Figure 1
Supplementary	Figure	1.	DNA	sequence	and	restriction	endonuclease	analysis	of	the	Val62	Gα11	mutation.	
(A)  DNA sequence analysis showed an A-to-G transition at c.184 (red arrow) within exon 2 of Gna11. (B) This 
sequence abnormality was predicted to lead to a missense substitution of Ile to Val at codon 62, resulting in the 
loss of a FokI restriction endonuclease (RE) site. (C) Restriction maps showing FokI digest would result in two 
products of 66bp and 160bp for the WT, and one 226bp product for the mutant (m). (D) RE digest of Gna11 exon 2 
PCR products demonstrating the A-to-G transition in Dsk7/+ and Dsk7/Dsk7 mice. S = size marker.
Supplementary Figure 2 
Supplementary Figure 2. Cells transiently transfected with WT and mutant Val62 pBI-CMV2-
GNA11 constructs overexpress the Ga11 protein. (A) Four separate Western blots of lysates from 
HEK-CaSR cells transiently expressing WT (Ile62) or mutant (Val62) pBI-CMV2-GNA11 constructs. 
Transient transfection with WT or mutant Val62 expression constructs resulted in overexpression of 
Gα11 compared to untransfected cells (UT). GAPDH was used as a housekeeping protein for Gα11 
blots, and calnexin for CaSR blots. (B) Densitometric analysis of Gα11 protein levels in each of the 
blots. Gα11 expression was normalized to levels of GAPDH and expressed as a fold-change of Gα11 
expression in UT cells. Gα11 was significantly overexpressed in transfected cells compared to UT cells. 
The expression of mutant Gα11 with endogenous WT Gα11 in transfected cells corresponded to the 
heterozygous situation in vivo. Data is expressed as mean±SEM of the 4 blots which represent 4 
independent lysates. Statistical analyses were performed using two-way ANOVA. **P<0.01.      
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Supplementary Figure 3. Comparsion of route of administration of NPS-2143 on plasma calcium and renal function in WT mice. (A) 
plasma adjusted-calcium, (B) plasma urea, and (C) plasma creatinine concentrations of untreated (UT) WT mice, and of WT mice given NPS-
2143 by oral gavage (OG) or intraperitoneal (IP) injection. Plasma biochemistry was measured at 1hr post-dose in NPS-2143-treated mice. 
Mean±SEM values for the respective groups are indicated by solid bars. Squares, males; circles, females. *P < 0·05,**P < 0·01, ***P < 0.001. A 
Kruskal-Wallis test followed by Dunn’s test for non-parametric pairwise multiple comparisons were used for analysis of A-C. 
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Supplementary Figure 4
Supplementary Figure 4.  Effect of NPS-2143 on plasma urea and creatinine of WT and Dsk7 mice at 0, 1, 2, 6 and 24hrs post-dose. 
(A-C) plasma urea and (D-F) plasma creatinine concentrations of WT (+/+), Dsk7/+ and Dsk7/Dsk7 mice, respectively. Mean±SEM values for 
the respective groups are indicated by solid bars. N=4-5 mice per study time-point. Squares, males; circles, females. *P < 0.05. A Kruskal-
Wallis test followed by Dunn’s test for non-parametric pairwise multiple comparisons were used for analysis of A-F.
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Supplementary Figure 5. Comparsion of effect of isoflurane general anesthesia versus topical local anesthesia on plasma concentra-
tions of calcium, phosphate and PTH. (A) plasma adjusted-calcium, (B) plasma phosphate, and (C) plasma PTH concentrations of +/+ (WT), 
Dsk7/+ and Dsk7/Dsk7 mice. Mean±SEM values for the respective groups are indicated by solid bars. Circles, +/+ mice; squares, Dsk7/+ mice; 
triangles, Dsk7/Dsk7 mice. Gen, general isoflurane anesthesia; Loc, local anesthesia.*P < 0·05, ***P < 0.001. A Kruskal-Wallis test followed by 
Dunn’s test for non-parametric pairwise multiple comparisons were used for analysis of A-C. 
